MedTrace Logo

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 927

Last updated 2026-04-30

No results posted yet for this study

Summary

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Conditions

  • Progressive Multiple Sclerosis (PMS)

Interventions

DRUG

Ocrelizumab

Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-28
Primary Completion
2026-10-22
Completion
2026-10-22
FDA Drug
Yes

Countries

  • United States
  • Bosnia and Herzegovina
  • Brazil
  • Canada
  • Colombia
  • Costa Rica
  • Czechia
  • Denmark
  • Egypt
  • France
  • Germany
  • Guatemala
  • Hungary
  • Ireland
  • Italy
  • Lebanon
  • Mexico
  • Morocco
  • Netherlands
  • Panama
  • Poland
  • Russia
  • Spain
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523858 on ClinicalTrials.gov